A Phase I safety study, using plasmid DNA vaccine-encoding CEA (CEA66 DNA) alongside GM-CSF in CRC patients, showed good tolerability with no signs of autoimmunity [64]. Here, CEACAM5 is linked to colorectal carcinoma.